血液病患者同基因造血干细胞移植后植入综合征的发生率及临床特征

OBJECTIVE: To explore the incidence and clinical characteristics of engraftment syndrome（ES）after syngeneic hematopoietic stem cell transplantation（syn-HSCT）in patients with hematological diseases. METHODS: The clinical data of 21 patients who received syn-HSCT at People's Hospital of Peking University from January 1994 to May 2018 were retrospectively analyzed. RESULTS: Seven（33.3％）of 21 patients developed ES. The onset of ES symptoms occurred at a median of 8（range: 5–13）days after HSCT, and the diagnosis of ES occurred at a median of 10（range: 7–14）days after HSCT. Steroids were administered immediately after the diagnosis of ES, the median time of symptom continuance was 2（range: 1–5）days, and all patients showed complete resolution of ES symptoms. In the multivariate analysis, patients with acute myeloid leukemia and faster neutrophil reconstitution were the risk factors for ES（HR＝15.298, 95％ CI 1.486–157.501, P＝0.022, and HR＝17.459, 95％ CI 1.776–171.687, P＝0.014）. Meanwhile, there was no significant difference in the overall survival and disease-free survival between patients with ES and those without ES. CONCLUSION: A high incidence of ES was observed in syn-HSCT recipients. Moreover, the prognosis of ES was excellent.